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A commentary on
Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders: systematic
review and meta-regression analysis
by Suliman, S., Hemmings, S. M. J. and Seedat, S. (2013). Front. Integr. Neurosci. 7:55. doi:
10.3389/fnint.2013.00055
Suliman et al. (2013) have performed a meta-analysis of studies comparing brain-derived neu-
rotrophic factor (BDNF) levels between patients with anxiety disorders and healthy controls.
BDNF is initially synthesized as a precursor (pre-pro-BDNF) that is sequentially cleaved into
BDNF (Reichardt, 2006). It acts on the TRKB receptor, promoting cellular proliferation, survival
and differentiation (Chao, 2003), and is considered to be an important mediator of enduring
experience-dependent changes in the brain (Park and Poo, 2013). Furthermore, BDNF and/or other
neurotrophic factors may be reduced in disorders such as depression (Duman and Monteggia,
2006), as has been proposed due to the presence of reduced hippocampal volume in depressed
patients (Sheline et al., 1996). Thus, there has been much interest in verifying if, across multi-
ple psychiatric disorders, including anxiety disorders, BDNF can be used as a biomarker. Suli-
man et al. (2013) have synthesized findings in from 8 studies, with a total of 1179 participants,
and their findings suggest that BDNF levels are reduced in individuals with anxiety disorders.
However, the authors also found that this effect is largely explained by findings in patients with
obsessive-compulsive disorder (OCD).
Much of the research regarding a potential role for BDNF in the mechanisms underlying psy-
chiatric disorders has been conducted in the context of animal-models of depressive disorders.
Mice with a knock-in of the human loss-of-function Val66Met BDNF gene polymorphism have
decreased dendrite length, as well as decreased spine-synapse density, maturity and function in the
hippocampus and the prefrontal cortex (Liu and Aghajanian, 2008). This allele is associated with
decreased BDNF transport to dendrites and activity dependent release of BDNF, ultimately leading
to atrophy of pyramidal neurons in these brain areas (Liu and Zhou, 2012). Furthermore, in tests
for depression-like behaviors, such as the learned helplessness or forced swim tests, hippocampal
BDNF infusions produce antidepressant-like effects (Shirayama et al., 2002), while targeted hip-
pocampal deletion of BDNF was sufficient to cause depression-like behaviors (Taliaz et al., 2010).
There is also evidence that the social defeat stress paradigm leads to downregulation of BDNF tran-
scripts and increases repressive histone methylation (Tsankova et al., 2006). Moreover, BDNF dele-
tion mutants are more vulnerable to stress, as shown by hypothalamo-pituitary axis hyperactivity,
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impaired working memory and increased depressive-like and
anxiety-like behavior (Yu et al., 2012). Finally, mice lacking
BDNF have impaired antidepressant responses (Monteggia et al.,
2004), and BDNF also seems to be required for the antidepres-
sant actions of fluoxetine on synaptic transmission, long-term
potentiation, ocular dominance plasticity and extinction train-
ing plasticity (Maya Vetencourt et al., 2008; Karpova et al., 2011;
Bath et al., 2012; Duman and Aghajanian, 2012). Ketamine, a new
and very promising antidepressant agent, also seems to require
BDNF: the synaptogenic actions of this agent are blocked in
mice with the Val66Met BDNF gene polymorphism and in BDNF
conditional mutant mice (Autry et al., 2011; Liu et al., 2012).
However, the view that depression is associated with low levels
of BDNF and that BDNF is necessary for antidepressant effects
may be too simplistic. In fact, some authors have shown that
BDNF has a pro-depressant effect in some brain regions, such
as the ventral tegmental area and the nucleus accumbens (Eisch
et al., 2003). There is also evidence that male mice with condi-
tional forebrain deletions of BDNF or its receptor do not show
depressive-like behavior (Zörner et al., 2003; Monteggia et al.,
2007)—arguing for a possible gender-specific role of BDNF in
depression (Carbone and Handa, 2013).
The evidence linking BDNF with anxiety-like behaviors in
animal models is not as abundant or clear. Foot-shock stress
leads to reductions of BDNF levels, arguing for a link between
BDNF and anxiety disorders such as post-traumatic stress disor-
der (Rasmusson et al., 2002). A causal link has been suggested
since conditional deletion of BDNF in the postnatal brain leads
to hyperactivity after exposure to stressors, and to higher lev-
els of anxiety-like behavior in the light/dark exploration test
(Rios et al., 2001). Furthermore, a variant BDNF mouse model
(BDNFMet/Met), with characteristics that are thought to repro-
duce the phenotype of humans with the Val66Met polymor-
phism, has increased anxiety-related behavior in the open field
and elevated plus maze (Chen et al., 2006). However, in genet-
ically modified mice overexpressing BDNF in excitatory neu-
rons of the forebrain, including the hippocampus, cortex and
amygdala, BDNF overexpression has an unexpected facilitatory
effect of anxiety-like behavior in the open field and in the ele-
vated plus maze, concomitant with increased spinogenesis in the
basolateral amygdala (Govindarajan et al., 2006). This genetic
manipulation also causes antidepressant effects, with improved
performance in the forced-swim test and an absence of chronic
stress-induced hippocampal atrophy. These findings can be inter-
preted in light of the contrast between hippocampus and amyg-
dala in depressive and anxiety disorders, with evidence for
increased amygdalar volume in anxiety disorders (Anand and
Shekhar, 2003) as opposed to decreased hippocampal volume
in depressive disorders (Sheline et al., 1996). In any case, this
interpretation does not reconcile all of the contradictory find-
ings reported in the literature. Other authors have found that,
in rats, a BDNF antisense oligodeoxynucleotide (which reduces
BDNF gene expression) provokes anxiety-like behaviors when
infused into the central and medial amygdala, but not basolat-
eral amygdala, and that these effects are rescued by BDNF co-
infusion (Pandey et al., 2006). Thus, evidence from studies in
animal-model studies shows, at best, that the precise relationship
between BDNF and anxiety is still unknown.
The meta-analysis by Suliman et al. (2013) raises novel
hypotheses for research in the relationship between BDNF and
anxiety disorders. The authors found evidence for reduced
peripheral BDNF levels in patients with anxiety disorders, mostly
due to effects in those suffering from OCD. In fact, in the fifth
edition of the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM), OCD has been excluded from the category of anxiety
disorders, and rather included in a novel category of obsessive-
compulsive and related disorders (American Psychiatric Associa-
tion, 2013). Several authors had previously suggested a potential
role for BDNF in OCD. Hall and colleagues showed a strong
association between BDNF gene sequence variants, including
the Val66Met variation, and OCD (Hall et al., 2003). Others
have confirmed that the Val66Met BDNF gene variant is a risk
allele for development of OCD, with possible gender specific
effects (Hemmings et al., 2008; Katerberg et al., 2009). However,
research exploring a possible pathophysiological role for BDNF
in OCD is lacking. The work by Suliman et al. (2013) summa-
rizes research that suggests lower BDNF levels in patients with
OCD, raising interesting possibilities for clinical research, such
as the possibility of testing peripheral BDNF as a biomarker for
this disorder. Furthermore, it also reinforces the need for further
research to clarify a potential role for BDNF in the neurobiology
of OCD.
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